In human hepatocellular carcinoma in cirrhosis, proliferating cell nuclear antigen (PCNA) is involved in cell proliferation and cooperates with P21 in DNA repair

Journal of Hepatology

Volumn 39, Issue 6, 2003, Pages 997-1003

  Gramantieri, Laura ^a   Trerè, Davide ^a   Chieco, Pasquale ^a   Lacchini, Michela ^a   Giovannini, Catia ^a   Piscaglia, Fabio ^a   Cavallari, Antonino ^a   Bolondi, Luigi ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Cell proliferation; DNA repair; Hepatocellular carcinoma; p21 waf1 cip1 sdi1; Proliferating cell nuclear antigen

Indexed keywords

CYCLINE; DETERGENT; KI 67 ANTIGEN; NUCLEAR PROTEIN; PROTEIN P21; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER GRADING; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA REPAIR; DNA SYNTHESIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

EID: 0346243786     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(03)00458-6     Document Type: Article

References (29)

1. Prosperi E. Multiple roles of the proliferating cell nuclear antigen: DNA replication, repair and cell cycle control. Progress Cell Cycle Res 1997;3:193-210.
2. Chang CD, Phillips P, Lipson KE, Cristofalo VJ, Baserga R. Senescent human fibroblasts have a post-transcriptional block in the expression of the proliferating cell nuclear antigen gene. J Biol Chem 1991;266:8663-8666.
3. Shivakumar CV, Brown DR, Deb S, Deb SP. Wild-type human p53 transactivates the human proliferating cell nuclear antigen promoter. Mol Cell Biol 1995;15:6785-6793.
4. Bravo R, MacDonald-Bravo H. Changes in the nuclear distribution of cyclin (PCNA) but not its synthesis depend on DNA replication. EMBO J 1985;4:655-661.
5. Bravo R, Macdonald-Bravo H. Existence of two populations of cyclin/proliferating nuclear cell antigen during the cell cycle: association with DNA replication sites. J Cell Biol 1987;105:1549-1554.
6. Celis JE, Celis A. Cell cycle-dependent variations in the distribution of the nuclear protein cyclin proliferating cell nuclear antigen in cultured cells: subdivision of S-phase. Proc Natl Acad Sci USA 1985;82:3262-3266.
7. Toschi L, Bravo R. Changes in cyclin/proliferating cell nuclear antigen distribution during DNA repair synthesis. J Cell Biol 1988;107:1623-1628.
8. Macleod KF, Sherry N, Hannon G, Beach D, Tokino T, Kinzler K, et al. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev 1995;9:935-944.
9. Cayrol C, Knibiehler M, Ducommun B. p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells. Oncogene 1998;16:311-320.
10. Pagano M, Theodoras AM, Tam SW, Draetta GF. Cyclin D1 inhibition of repair and replicative DNA synthesis in human fibroblasts. Genes Dev 1994;8:1627-1639.
11. Savio M, Stivala LA, Scovassi AI, Bianchi L, Prosperi E. p21waf1/cip1 protein associates with the detergent-insoluble form of PCNA concomitantly with disassembly of PCNA at nucleotide excision repair sites. Oncogene 1996;13:1591-1598.
12. Ballardini G, Groff P, Zoli M, Bianchi GP, Giostra F, Francesconi R, et al. Increased risk of hepatocellular development in patients with cirrhosis and with high hepatocellular proliferation. J Hepatol 1994;20:218-222.
13. Donato MF, Arosio E, Del Ninno E, Ronchi G, Lampertico P, Morabito A, et al. High rates of hepatocellular carcinoma in cirrhotic patients with high liver cell proliferative activity. Hepatology 2001;34:523-528.
14. Kitamoto M, Nakanishi T, Kira S, Kawaguchi M, Nakashio R, Suemori S, et al. The assessment of proliferating cell nuclear antigen immunohistochemical staining in small hepatocellular carcinoma and its relationship to histologic characteristics and prognosis. Cancer 1993;72:1859-1865.
15. Ng IO, Lai EC, Fan ST, Ng M, Chan AS, So MK. Prognostic significance of proliferating cell nuclear antigen expression in hepatocellular carcinoma. Cancer 1994;73:2268-2274.
16. Suehiro T, Matsumata T, Itasaka H, Yamamoto K, Kawahara N, Sugimachi K. Clinicopathologic features and prognosis of resected hepatocellular carcinomas of varied sizes with special reference to proliferating cell nuclear antigen. Cancer 1995;76:399-405.
17. Tsopanoumichalou M, Kouroumalis E, Ergazaki M, Spandilos DA. Loss of heterozygosity and microsatellite instability in human non-neoplastic hepatic lesions. Liver 1999;19:305-311.
18. Nagai H, Pineau P, Tiollais P, Buendia MA, Dejean A. Comprehensive allelotyping of human hepatocellular carcinoma. Oncogene 1997;14:2927-2933.
19. Yeh SH, Chen PJ, Shau WY, Chen YW, Lee PH, Chen JT, et al. Chromosomal allelic imbalance evolving from liver cirrhosis to hepatocellular carcinoma. Gastroenterology 2001;121:699-709.
20. Edmondson HA, Steiner PE. Primary carcinoma of the liver. A study of 100 cases among 48,900 necropsies. Cancer 1954;7:462-503.
21. Sadaie MR, Mathews MB. Immunochemical and biochemical analysis of the proliferating cell nuclear antigen (PCNA) in HeLa cells. Exp Cell Res 1986;163:423-433.
22. Snedecor GW, Cochran WG. Statistical methods. Ames: Iowa State University Press; 1990.
23. Cleveland WS, McGill R. Graphical perception and graphical methods for analyzing scientific data. Science 1985;229:828-833.
24. Qin LX, Tang ZY, Ma ZC, Wu ZQ, Zhou XD, Ye QH, et al. P53 immunohistochemical scoring: an independent prognostic marker for patients after hepatocellular carcinoma resection. Word J Gastroenterol 2002;8:459-463.
25. Jaumot M, Grana X, Giordano A, Reddy V, Agell N, Bachs O. Cyclin/CDK2 complexes in the nucleus of HeLa cells. Biochem Biophys Res Commun 1994;203:1527-1534.
26. Pan ZQ, Reardon JT, Li L, Flores-Rozas H, Legerski R, Sancar A, et al. Inhibition of the nucleotide excision repair by the cyclin dependent kinase inhibitor p21. J Biol Chem 1995;270:22008-22016.
27. Qin LF, Ng IOL, Fan ST, Ng M. p21/waf1, p53 and PCNA expression and p53 mutation status in hepatocellular carcinoma. Int J Cancer 1998;79:424-428.
28. Lacombe L, Maillette A, Meyer F, Veilleux C, Moore L, Fradet Y. Expression of p21/waf1/cip1 predicts PSA failure in locally advanced prostate cancer treated by prostatectomy. Int J Cancer 2001;95:135-139.
29. Ceccarelli C, Santini D, Chieco P, Lanciotti C, Taffurelli M, Paladini G, et al. Quantitative p21/waf1/p53 immunohistochemical analysis defines groups of primary invasive breast carcinomas with different prognostic indicators. Int J Cancer 2001;95:128-134.